

# Resource Summary Report

Generated by [PRECISE-TBI](#) on Jul 30, 2026

## Perkin Elmer: IVIS Spectrum In Vivo Imaging System

RRID:SCR\_018621

Type: Tool

### Proper Citation

Perkin Elmer: IVIS Spectrum In Vivo Imaging System (RRID:SCR\_018621)

### Resource Information

**URL:** <https://www.perkinelmer.com/product/ivis-instrument-spectrum-120v-andor-c-124262>

**Proper Citation:** Perkin Elmer: IVIS Spectrum In Vivo Imaging System (RRID:SCR\_018621)

**Description:** In vivo imaging system that combines two dimensional and three dimensional optical tomography in one platform. The system uses leading optical technology for preclinical imaging research and development best for non-invasive longitudinal monitoring of disease progression, cell trafficking and gene expression patterns in living animals.

**Resource Type:** instrument resource

**Keywords:** In vivo imaging system, Instrument, Equipment, USEDit, Perkin Elmer, ABRF

**Resource Name:** Perkin Elmer: IVIS Spectrum In Vivo Imaging System

**Resource ID:** SCR\_018621

**Alternate IDs:** Model\_Number\_IVIS, SCR\_020397

**Alternate URLs:** [https://resources.perkinelmer.com/lab-solutions/resources/docs/bro\\_010572b\\_01\\_prd\\_ivis\\_spectrum.pdf](https://resources.perkinelmer.com/lab-solutions/resources/docs/bro_010572b_01_prd_ivis_spectrum.pdf)

**Record Creation Time:** 20220129T080341+0000

**Record Last Update:** 20260725T190853+0000

### Ratings and Alerts

No rating or validation information has been found for Perkin Elmer: IVIS Spectrum In Vivo Imaging System.

No alerts have been found for Perkin Elmer: IVIS Spectrum In Vivo Imaging System.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 37 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [PRECISE-TBI](#) .

Khan MA, et al. (2026) Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression. *Cancer letters*, 638, 218160.

Li H, et al. (2026) PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation. *Oncogene*, 45(4), 577.

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. *Cancer research*, 85(11), 1978.

Laplante P, et al. (2025) Effect of MisMatch repair deficiency on metastasis occurrence in a syngeneic mouse model. *Neoplasia (New York, N.Y.)*, 62, 101145.

Wang X, et al. (2025) Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor-Ligand Interactions That Instructs Intratumoral ??T-cell Activity. *Cancer research*, 85(2), 277.

Bernasconi-Bisio F, et al. (2025) Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML. *Molecular therapy. Oncology*, 33(1), 200949.

Lindland K, et al. (2025) Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. *Molecular cancer therapeutics*, 24(9), 1415.

Harre P, et al. (2025) Dietary ?-3 polyunsaturated fatty acids (PUFAs) reduce cholesterol-driven non-small cell lung cancer (NSCLC) progression in mouse models of disease. *Communications medicine*, 5(1), 432.

Shen H, et al. (2025) Engineered commensals for targeted nose-to-brain drug delivery. *Cell*, 188(6), 1545.

Mogol AN, et al. (2025) ACSS2-Mediated Metabolic-Epigenetic Crosstalk Drives Fulvestrant Resistance and Represents a Novel Therapeutic Target. *bioRxiv : the preprint server for biology*.

Lee W, et al. (2025) Protocol for assessing mobilization of peritoneal B cells to the pre-metastatic omentum in an orthotopic mouse model of ovarian cancer. *STAR protocols*, 6(2), 103806.

Maurya SK, et al. (2025) Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 921.

Crawford KJ, et al. (2025) Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. *Molecular cancer*, 24(1), 208.

Prabagar MG, et al. (2024) THE STING AGONIST VB-85247 INDUCES DURABLE ANTITUMOR IMMUNE RESPONSES BY INTRAVESICAL ADMINISTRATION IN A NON-MUSCLE INVASIVE BLADDER CANCER. *Cancer research*.

Saggese P, et al. (2024) Glucose Deprivation Promotes Pseudohypoxia and Dedifferentiation in Lung Adenocarcinoma. *Cancer research*, 84(2), 305.

Mustafa EH, et al. (2024) Selective inhibition of CDK9 in triple negative breast cancer. *Oncogene*, 43(3), 202.

Ullah I, et al. (2024) Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens. *iScience*, 27(3), 109049.

Jessa S, et al. (2024) FOXR2 targets LHX6+/DLX+ neural lineages to drive CNS neuroblastoma. *Cancer research*.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.

Springer AD, et al. (2024) Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma. *Cancer research communications*, 4(10), 2660.